Harmony (HRMY) Reports Q1 2026 Earnings with Revenue Growth and Guidance
Harmony Biosciences reported $215.4 million in net revenue for Q1 2026, a 17% year-over-year increase driven by WAKIX performance despite market access challenges. The company reiterated its full-year guidance of $1 billion to $1.04 billion and highlighted ongoing pipeline advancements.
Tickers: $HRMY